Side-by-side comparison of AI visibility scores, market position, and capabilities
Consumer telehealth platform with Q3 2025 revenue of $599M (+49% YoY); 2.47M subscribers; 2025 guidance $2.3-2.4B; acquiring ZAVA for European expansion; GLP-1 weight loss, hair, and sexual health treatments shipped directly to subscribers.
Hims & Hers is a consumer telehealth and pharmacy platform founded in 2017 in San Francisco by Andrew Dudum, built on the mission of making high-quality healthcare affordable and stigma-free for conditions that people historically avoided treating due to embarrassment, cost, or access barriers. The platform's core technology combines a direct-to-consumer digital health interface with an integrated pharmacy network, enabling patients to complete asynchronous or synchronous consultations with licensed clinicians and receive prescription treatments — including compounded medications — delivered directly to their homes.\n\nHims & Hers serves patients across sexual health, hair loss, mental health, dermatology, and weight management. The company's expansion into GLP-1 compounded weight loss medications has been a significant growth catalyst, capitalizing on surging consumer demand for semaglutide and tirzepatide alternatives during periods of branded drug shortages. With 2.47 million subscribers and a subscription-centric business model, the platform generates predictable recurring revenue from patients on ongoing treatment protocols. The company's 2025 acquisition of ZAVA expands its addressable market into European telehealth markets.\n\nHims & Hers reported Q3 revenue of $599 million, a 49% year-over-year increase, and issued full-year 2025 guidance of $2.3 to $2.4 billion — a scale that makes it one of the largest consumer telehealth companies in the world. The company's ability to compound subscriber growth with expanding treatment categories and international expansion through ZAVA provides multiple vectors for continued revenue acceleration. As healthcare consumerization intensifies and patients increasingly manage chronic conditions through digital-first platforms, Hims & Hers' brand recognition, integrated pharmacy infrastructure, and subscription model give it a durable position in consumer health.
FY2024 Revenue: $372.8B (+4.2% YoY) | Net income: $4.6B (down from $8.4B) | Operating income: $8.5B (-38% YoY) | Q4 2024: $97.7B | Healthcare benefits segment challenged
CVS Health Corporation is one of the largest healthcare companies in the United States, formed through a series of major acquisitions that transformed CVS Pharmacy — a retail drugstore chain founded in Lowell, Massachusetts in 1963 — into a vertically integrated healthcare enterprise. Key acquisitions include Caremark Rx (pharmacy benefit management, 2007), Aetna (health insurance, $69 billion, 2018), and Oak Street Health (primary care clinics, 2023). CVS Health's model positions the company as a healthcare touchpoint spanning insurance enrollment, prescription management, and clinical care delivery.\n\nCVS Health's segments include Health Care Benefits (Aetna insurance for employer groups, Medicare, and Medicaid), Health Services (Caremark PBM, specialty pharmacy, infusion), and Pharmacy & Consumer Wellness (retail operations). CVS operates 9,000+ pharmacy locations and is expanding MinuteClinic and HealthHUB formats that co-locate clinical services with pharmacy for primary and chronic care management. The company also operates pharmacy-only conversion locations removing front-end retail to concentrate on health services.\n\nCVS Health reported FY2024 revenue of $372.8 billion (+4.2% YoY) with net income of approximately $4.6 billion. Near-term pressure on Aetna's Medicare Advantage business — elevated medical cost ratios from post-pandemic care utilization — has driven benefit redesigns and market exits. Despite these headwinds, CVS Health's vertically integrated model combining PBM leverage, insurance membership, and retail pharmacy access represents a structurally unique healthcare asset at scale.
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.